Rebyota denied due to quantity / dose limits by Cigna?
Quantity-limit denials usually flip when the appeal documents the clinically appropriate dose for the patient's weight, kidney function, or escalation schedule, citing the FDA label or specialty-society guideline.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Cigna typically requires
Cigna's specific coverage criteria for rebyota are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Cigna angle on Rebyota
## Why Cigna Limits Rebyota Quantities — and Why You Can Appeal
Rebyota (fecal microbiota, live-jslm) is an FDA-approved single-course therapy for preventing recurrence of Clostridioides difficile (C. diff) infection. Cigna's quantity limits for Rebyota typically correspond to the standard treatment course described in the FDA-approved prescribing information. A quantity-limit denial usually occurs when the prescription as written exceeds the authorized quantity per coverage period — sometimes because a patient requires a repeat course due to a subsequent C. diff recurrence after an initial treatment.
## Why This Denial Is Appealable
Quantity limits are set for average patients following a single episode; they may not account for patients who experience a C. diff recurrence after an initial Rebyota course, or for other clinical circumstances requiring a second course. If your prescriber has determined that a quantity exceeding the limit is medically necessary — with documented clinical justification consistent with the FDA prescribing label — you have the right to appeal. The key is demonstrating that the additional quantity is not being requested arbitrarily but reflects a documented clinical need.
## Federal Appeal Framework
- Internal appeal: File within the deadline on the denial notice. Under ERISA Section 503 (employer plans) and ACA Section 2719 (non-grandfathered plans), you are entitled to a full-and-fair review and access to the quantity-limit policy criteria.
- External review: Available after exhausting internal remedies. The standard window is approximately 4 months from the final internal denial.
- Expedited review: Request if the clinical situation is urgent — active or serious recurrent C. diff can meet the urgency threshold.
## Appeal Timeline
1. Request Cigna's quantity-limit policy for Rebyota in writing. 2. Identify the specific quantity authorized and what your prescription requests. 3. Have your prescriber document the clinical basis for the quantity ordered. 4. Submit the internal appeal with supporting records. 5. If denied, file for external review promptly.
## Documentation to Gather
- Prior Rebyota course documentation: Records showing the prior course was administered, the date, and the subsequent recurrence that necessitates an additional course.
- Recurrence confirmation: Lab results confirming the new or subsequent C. diff episode.
- Prescriber medical-necessity letter: Should explain why the quantity ordered is consistent with the FDA-approved prescribing information and medically necessary for this patient's clinical course.
- Clinical notes: Specialist documentation of the recurrence, treatment rationale, and clinical status.
## Criteria-Mapping Structure
Obtain Cigna's quantity-limit policy for Rebyota. Map each criterion:
| Quantity-Limit Criterion | Supporting Evidence | |---|---| | Standard course quantity authorized | Confirm prescription matches FDA-label course definition | | Basis for quantity exceeding limit | Lab-confirmed recurrence date; prescriber clinical rationale | | Consistent with FDA prescribing information | Prescribing label language; prescriber attestation |
Quantity-limit appeals supported by documented recurrence and a prescriber letter referencing the FDA label are among the more straightforward category of coverage appeals to win.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →